XTL Biopharmaceutica (Israel) Probability of Future Stock Price Finishing Over 25.64
| XTLB Stock | ILS 6.50 0.60 10.17% |
XTL |
XTL Biopharmaceutica Target Price Odds to finish over 25.64
The tendency of XTL Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over S 25.64 or more in 90 days |
| 6.50 | 90 days | 25.64 | close to zero percent |
Based on a normal probability distribution, the odds of XTL Biopharmaceutica to move over S 25.64 or more in 90 days from now is close to zero percent (This XTL Biopharmaceuticals probability density function shows the probability of XTL Stock to fall within a particular range of prices over 90 days) . Probability of XTL Biopharmaceuticals price to stay between its current price of S 6.50 and S 25.64 at the end of the 90-day period is about 78.02 .
Assuming the 90 days trading horizon the stock has the beta coefficient of 1.69 . This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, XTL Biopharmaceutica will likely underperform. Additionally XTL Biopharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. XTL Biopharmaceutica Price Density |
| Price |
Predictive Modules for XTL Biopharmaceutica
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as XTL Biopharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.XTL Biopharmaceutica Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. XTL Biopharmaceutica is not an exception. The market had few large corrections towards the XTL Biopharmaceutica's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold XTL Biopharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of XTL Biopharmaceutica within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.61 | |
β | Beta against Dow Jones | 1.69 | |
σ | Overall volatility | 1.63 | |
Ir | Information ratio | -0.1 |
XTL Biopharmaceutica Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of XTL Biopharmaceutica for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for XTL Biopharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| XTL Biopharmaceutica generated a negative expected return over the last 90 days | |
| XTL Biopharmaceutica has high historical volatility and very poor performance | |
| XTL Biopharmaceutica has high likelihood to experience some financial distress in the next 2 years | |
| XTL Biopharmaceuticals has accumulated about 5.06 M in cash with (1.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 16.0% of the company outstanding shares are owned by insiders |
XTL Biopharmaceutica Technical Analysis
XTL Biopharmaceutica's future price can be derived by breaking down and analyzing its technical indicators over time. XTL Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of XTL Biopharmaceuticals. In general, you should focus on analyzing XTL Stock price patterns and their correlations with different microeconomic environments and drivers.
XTL Biopharmaceutica Predictive Forecast Models
XTL Biopharmaceutica's time-series forecasting models is one of many XTL Biopharmaceutica's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary XTL Biopharmaceutica's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about XTL Biopharmaceuticals
Checking the ongoing alerts about XTL Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for XTL Biopharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| XTL Biopharmaceutica generated a negative expected return over the last 90 days | |
| XTL Biopharmaceutica has high historical volatility and very poor performance | |
| XTL Biopharmaceutica has high likelihood to experience some financial distress in the next 2 years | |
| XTL Biopharmaceuticals has accumulated about 5.06 M in cash with (1.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 16.0% of the company outstanding shares are owned by insiders |
Other Information on Investing in XTL Stock
XTL Biopharmaceutica financial ratios help investors to determine whether XTL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTL with respect to the benefits of owning XTL Biopharmaceutica security.